HONG KONG, Aug. 29, 2025 /PRNewswire/ — On the morning of 29 August, Guo Guangchang, Chairman of Fosun International, stated at the Company’s 2025 interim results presentation that Fosun will continue to increase investment in biopharmaceuticals and focus on deepening and thoroughly developing its advantageous industries to secure a commanding global position.

The interim results presentation was held in Shanghai this morning, with attendees including Chairman Guo Guangchang, Co-Chairman Wang Qunbin, Co-CEO Chen Qiyu, Co-CEO Xu Xiaoliang, CFO Gong Ping, along with numerous investors and analysts.

Guo Guangchang highlighted that Fosun achieved significant breakthroughs across several business segments in the first half of 2025, particularly in the biopharmaceutical segment. Moving forward, Fosun will seize growth opportunities and aim for breakthrough progress through technology innovation.

Regarding investor concerns about innovative drug R&D, Guo Guangchang explained that within Fosun’s robust pipeline, it has reserved a batch of important products. Fosun’s pharmaceutical innovation will extend beyond just Henlius. It also has Fosun Kite’s CAR-T therapy, along with innovative drugs from its established product divisions, all of which have immense potential.

Guo Guangchang said, “I have been emphasizing to our team that we shouldn’t just sell off all our innovative drugs. Both licensing in and licensing out are important. Some products may command a high price if simply licensed out, but we are not in a rush. We should continue to advance our R&D to make these products the best in the world.”

Guo Guangchang said that Fosun previously stated its vision is to help everyone to live healthily and happily to the age of 121. In particular, Fosun’s self-imposed goal is that cancer should be curable. With the current trajectory of pharmaceuticals development, this increasingly feels like an achievable reality. Many cancers today are already preventable, treatable, detectable, curable, or can be managed as chronic, controllable conditions.

Guo Guangchang believes that future cancer treatment will not rely on a single approach, it will involve a combination of approaches, including drugs, devices, and multi-molecule therapies, similar to a cocktail therapy. Fosun possesses a distinct advantage in these areas due to its comprehensive strategic layout and broad industry presence in the Health segment. Future cancer treatment will require comprehensive capability, and this comprehensive capability is precisely one of Fosun Pharma’s hallmark characteristics.

He emphasized that what sets Fosun apart from other Chinese pharmaceutical companies is Fosun’s commitment to building its own global R&D capabilities, global clinical capabilities, and global sales capabilities. This is Fosun’s unwavering mission—and the fundamental path for it to become a truly global pharmaceutical leader.

When sharing his insights on building a business, Guo Guangchang said that nowadays, it is very difficult to establish true competitive strength without at least a decade or two of effort. For example, Henlius, now 15 years old, saw its initial 10-plus years involve investments exceeding RMB10 billion with virtually no returns; it was all about long-term investment. Fosun’s two domestic insurance companies, Fosun United Health Insurance and Pramerica Fosun Life Insurance, one founded 8 years ago and the other 13 years ago, are now entering a period of comprehensive profitability.

He stated that Fosun’s excitement doesn’t lie in new sectors; it lies in deepening and thoroughly developing industries that it has established significant industry advantages, striving to achieve breakthroughs, accelerate growth, and ascend to the pinnacle within these mature sectors, securing a commanding global position.

Guo Guangchang said, “Even old wine needs innovation. Fosun’s Shede Spirits has recently conducted innovative R&D on high-alcohol traditional baijiu and launched a new liquor with 29% ABV, named ‘Shede Zizai’, meaning ‘Shede at Ease’. It retains the flavor of aged liquor while meeting today’s younger generation’s pursuit of health.”

SHANGHAI, Aug. 29, 2025 /PRNewswire/ — United Imaging Healthcare (SSE: 688271), a global leader in advanced medical imaging and radiotherapy equipment, has released its financial results for the first half of 2025, maintaining steady growth. The company’s revenue and net profit attributable to ordinary shareholders after deducting non-recurring profit or loss reached CNY 6.02 billion and 0.97 billion for 2025H1, representing a year-over-year increase of 12.79% and 21.01% respectively.

The company’s revenue growth was primarily fueled by continuous launch of innovative high-end products, now widely recognized in the market, alongside the expansion in overseas markets and the growth of service revenues. In the first half of 2025, overseas revenue reached CNY 1.14 billion and service revenue reached CNY 0.82 billion, accounting for 18.99% and 13.56% of total revenue respectively, both reaching record highs.

R&D investment plays a pivotal role in driving innovation. In the first half of 2025, United Imaging Healthcare’s R&D investment reached CNY 1.14 billion, representing a year-over-year increase of 12.09%, primarily allocated to next-generation platform technology and innovations in core products.

As of the date of this report, the company had introduced over 140 innovative products globally, of which 53 were cleared by the U.S. FDA through the 510(k) process and 57 were CE certified under MDR/MDD. The company is accelerating the commercial deployment of its AI-enabled products, with FDA-authorized AI medical equipment exceeding 20, including uCT ATLAS Astound, uMI Panorama, uMI Panvivo, uMR Jupiter, uMR Omega and uMR 680.

Multiple globally impactful products were launched in the first half of the year. uMR Ultra enables high-clarity soft-tissue diagnostics through real-time high-definition imaging. uCT SiriuX (not yet cleared or approved by the FDA or CE marked for commercial use) provides a proprietary dual-wide gantry architecture. uAngio AVIVA received FDA clearance, featuring industry-first intelligent voice-assist technology for hands-free operation during procedures.

The global medical equipment industry continues to expand. The company’s overseas orders maintained robust growth particularly in premium and innovative products during the first half of 2025.

In North America, United Imaging Healthcare’s premium imaging equipment have covered over 70% of U.S. states, accumulating more than 400 installations by the end of 2025H1.

In Europe, United Imaging Healthcare has successfully delivered a significant number of high-end medical equipment and established a strong market presence in over 20 countries, including UK, Germany, Italy, France, Spain, Ukraine, Poland, Greece, Romania, and Hungary.

In Asia-Pacific and Latin America, United Imaging Healthcare achieved key breakthroughs and landmark installations. Notably, the company secured a major account and deployed systems at Singapore General Hospital, which is ranked first in Asia and ninth worldwide.

Looking ahead, United Imaging Healthcare will continue to expand its global presence, accelerating the delivery of premium medical equipment. At the same time, the company will strengthen its AI innovation to drive the intelligent and precision transformation of medical imaging equipment, providing more efficient and accurate solutions for the global healthcare industry.

JIUJIANG, China, Aug. 29, 2025 /PRNewswire/ — On 29 August, “JIUJIANG: THE ESSENCE OF CHINESE LANDSCAPES” 2025 Jiujiang Cultural & Tourism Singapore Roadshow took place at Orchard Hotel. Present were Wang Jianxin, Party Secretary & Director of Jiujiang Municipal Bureau of Culture, Radio, TV and Tourism; Shi Lan, Party Secretary & Director of Jiujiang Municipal Commerce Bureau; Xiao Fangmin, President of the National Association of Travel Agents Singapore (NATAS); Kuang Rongfa, Director of Lushan Municipal Bureau; Wu Shuguang, Director of Lushan West Sea Bureau; Deng Feng, Party Secretary of Yongxiu County Bureau; and over 100 representatives from scenic spots, travel agencies and media of both sides.

In his address, Wang Jianxin noted that Singapore and Jiujiang, both thriving on water and commerce, share time-honoured ties. Jiujiang Party Secretary Liu Wenhua has led several delegations to Singapore, while the Singapore Consul-General in Xiamen has praised Jiujiang’s location and business climate. He invited Singapore visitors to fly direct to Nanchang Changbei Airport and “start from Singapore, relax in Xunyang”.

Xiao Fangmin responded by pledging deeper two-way visitor exchanges.

During the presentations, Kuang Rongfa showcased the UNESCO World Cultural Landscape of Lushan through five “Yōu” themes (history, culture, scenery, lifestyle and serenity). Wu Shuguang unveiled Lushan West Sea’s thousand-island vistas, wellness retreats, water sports and intangible-heritage experiences. Deng Feng highlighted Yongxiu’s Poyang Lake wetlands—”painted lakes and a kingdom of migratory birds”. A bespoke Jiujiang itinerary video for the Singapore market premiered simultaneously.

Duck & Tour (Singapore) signed with Jiangxi Yuanda International Travel, and Hong Thai Travel (Singapore) with China Travel Service Jiujiang. The agreements mark Jiujiang’s deeper entry into the Southeast Asian market and lay a solid foundation for Belt-and-Road win-win tourism cooperation.

FOSHAN, China, Aug. 29, 2025 /PRNewswire/ — Midea Group has achieved a historic financial milestone, with revenue exceeding RMB 100 billion for two consecutive quarters and hitting a remarkable RMB 252 billion in the first half (H1) of 2025. This represents a 15.7% year-over-year (YoY) increase, with profits surged to RMB 26 billion, marking a 25% rise.

Revenue in Mainland China grew by 14.2%, demonstrating Midea Group’s strong market penetration in China. Internationally, the company’s revenue experienced a notable 17.7% leap. OBM (Original Brand Manufacturing) operations recorded a considerable revenue growth, with an over 30% YOY increase in e-commerce sales revenue. During 2025 H1, Midea Group completed the acquisition of Teka Group (excludingTeka’s Russian subsidiary).

The consumer (ToC) segment reported a revenue of RMB 167 billion, an 13.3% increase, while commercial and industrial solution (ToB) revenues rose by 20% .

The new energy and industrial technology segment reached RMB 22 billion, intelligent building technology revenues were at RMB 19.5 billion, and robotics and automation revenues stood at RMB 15.1 billion.

Midea invested RMB 8.8billion in R&D(research and development), with a 14% increase in the first half of 2025. The acquisition of over 5500 new patents in 2025 has placed Midea among the top 10 global patent holders. Its global network of 38 R&D centers and 63 production bases highlights its leadership in smart manufacturing and digital transformation.

Midea Group has maintained a consistent presence in the Fortune China ESG (Environmental, Social, and Governance) impact, and 2025 MSCI ESG rating”to A. The company’s innovative edge is reflected in its advanced manufacturing facilities, including 37 green factories, 13 green supply chain, 9 5G-enabled, and 6 “World Lighthouse Factories”. On August 26, the Midea Washing Machine Jingzhou（Hubei）Factory received certification from the World Records Certification Agency (WRCA) based in London as” The World’s First Intelligent Factory with Multi-scene Coverage of Excellence”.

Globally recognized, Midea Group has maintained a consistent presence in the Fortune Global 500, securing the 246^TH spot in 2025, and as the 184^TH company in the 2025 Forbes Global 2000 list, affirming its strong global brand presence and market influence.

Despite economic volatility, Midea Group has demonstrated resilience through significant semi-annual revenue growth. With a strategic focus on innovation, operational efficiency, and global expansion, the company is positioned for continued growth, committed to investing in R&D and digital transformation.

The H1 2025 financial results highlight Midea Group’s robust performance across both domestic and international markets, reflecting a balanced strategy that integrates technological innovation, operational excellence and a strong global presence.